[Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
The effects of drugs with hypolipidemic properties in the prevention of the atherothrombotic vascular disease, go further than reducing serum lipids, suggesting that there are other nonlipid-related mechanisms involved; the maintenance of appropriate haemostatic balance being one of them. The objective of this investigation was a drug intervention with ciprofibrat in hyperlipidemic people with high level of plasmatic fibrinogen with the purpose of knowing the effects of the drug over these risk factors and other haemostatic parameters. Forty people, both sexes, 20 of them apparently healthy and the other 20 with clinical and angiographic evidence of coronary artery disease, were randomized to receive 100 mg of ciprofibrat or placebo during an average of 56 weeks. All of them had a clinical exam, EKG and stress test. Laboratory exams included lipid profile, plasma fibrinogen (Fg), VII factor, vonWillebrand factor, protein C (PC) and the tissue plasminogen activator with samples taken every 8 weeks. The Ciprofibrat group showed significant changes of lipids: cholesterol -23%, triglycerides -31%, high-density lipoprotein (HDLc) +24% and very low-density lipoprotein -23%, except low-density lipoprotein -24%. The haemostatic parameters in 40 weeks showed that Fg decreased 21% (p = 0.001), decreasing to 9% at the end of the follow-up. In the placebo group the HDLc showed a 10% increase (p = 0.02), PC reduced to 20% (p = 0.01) and Fg kept blood levels close to basal line, descending 10% at the end of the follow-up. In this study, the use of ciprofibrat in patients with high risk of developing atherothrombotic events, showed efficiency and security in handling hyperlipidemia, such as keeping and appropriate haemostatic balance.
Servicio de Cardiología, Hospital Miguel Pérez Carreño (HMPC), Caracas, Venezuela. remcardiol@hotmail.com
Raúl A
RA
Espinosa
Elsy
E
Rodríguez-Roa
Elena
E
Nagy
Mercedes E
ME
Mijares
Alvaro
A
Rodríguez-Larralde
Amparo
A
Gil
Ulf
U
Lundberg
Zoila
Z
Carvajal
Luis
L
Castillo
Carmen L
CL
Arocha-Piñango
D000293:Adolescent; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D003324:Coronary Artery Disease / Q000097:blood* / Q000150:complications*; D005260:Female; D058607:Fibric Acids; D005340:Fibrinogen / Q000032:analysis*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000150:complications* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood*
D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D014280:Triglycerides; D002995:Clofibric Acid; D005340:Fibrinogen; D002784:Cholesterol; C019304:ciprofibrate